Replies to post #121741 on Savvy Trades and Investments

[SSKILLZ1]

JAZZ

Brought at $134.36

Decided to buy it back on this mini pullback from the upper 140's after earnings.

1) JAZZ is guiding for $22.50-24.00 up from $20.90, which means they are showing solid growth. This earnings chart shows the progression for the last couple of years. Which I think is impressive.

 
 FY 25 Estimate $22.50-24.00 
 FY 24 $20.90 
 FY 23 $18.29 
 FY 22 $13.20 
 

2) JAZZ is a consistent revenue grower shown by this long-term chart. I find this growth impressive.

 
 FY 14 1,173 
 FY 15 1,325 
 FY 16 1,488 
 FY 17 1,619 
 FY 18 1,891 
 FY 19 2,162 
 FY 20 2,364 
 FY 21 3,094 
 FY 22 3,659 
 FY 23 3,834 
 FY 24 4,069 
 FY 25 Estimate 4150-4400 
 

3) Zanidatamab is hopefully just getting started here and will be a huge drug in the future. if approved for all of the things they will try to approve it for it could have 2 billion + peak potential. The drug is already approved for BTC, albeit that is a smaller market opportunity.

4) JAZZ has been buying shares back. So that is a plus.

Conclusion: I like JAZZ here and will definitely buy more on weakness as I feel this price is significantly undervalued. I could certainly make a case for 10x multiple easy and even than it would be cheap which put FV around $235, which means it is a very attractive investment here. All is just my opinion, and I could always be wrong though.